Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 738

1.

(18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.

Al-Ibraheem A, Buck AK, Benz MR, Rudert M, Beer AJ, Mansour A, Pomykala KL, Haller B, Juenger H, Scheidhauer K, Schwaiger M, Herrmann K.

Cancer. 2013 Mar 15;119(6):1227-34. doi: 10.1002/cncr.27866. Epub 2012 Dec 11.

2.

Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.

Arush MW, Israel O, Postovsky S, Militianu D, Meller I, Zaidman I, Sapir AE, Bar-Shalom R.

Pediatr Blood Cancer. 2007 Dec;49(7):901-5.

PMID:
17252575
3.

The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence after curative gastrectomy.

Lee JE, Hong SP, Ahn DH, Jeon TJ, Kang MK, Kwon CI, Ko KH, Hwang SG, Park PW, Rim KS.

Yonsei Med J. 2011 Jan;52(1):81-8. doi: 10.3349/ymj.2011.52.1.81.

4.

Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.

Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Fukasawa I, Inaba N, Suganuma N, Sugimura K.

Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1439-48. doi: 10.1007/s00259-008-0776-3. Epub 2008 Apr 17.

PMID:
18418592
5.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
6.

Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors.

Bischoff M, Bischoff G, Buck A, von Baer A, Pauls S, Scheffold F, Schultheiss M, Gebhard F, Reske SN.

Arch Orthop Trauma Surg. 2010 Jul;130(7):819-27. doi: 10.1007/s00402-009-0937-2. Epub 2009 Jul 28.

PMID:
19636577
7.

[Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].

Xu XX, Cheng J, Xu WG, Dai D, Song XY, Ma WC, Zhu L, Zhu X.

Zhonghua Zhong Liu Za Zhi. 2012 May;34(5):364-8. doi: 10. 3760/cma.j.issn.0253-3766.2012.05.010. Chinese.

PMID:
22883458
8.
9.

F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas.

Iagaru A, Quon A, McDougall IR, Gambhir SS.

Clin Nucl Med. 2006 Dec;31(12):754-60.

PMID:
17117068
10.

Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging.

Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE.

Radiology. 2007 Dec;245(3):839-47.

PMID:
18024454
12.

Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer.

Schmidt GP, Baur-Melnyk A, Haug A, Utzschneider S, Becker CR, Tiling R, Reiser MF, Hermann KA.

Eur Radiol. 2009 Jun;19(6):1366-78. doi: 10.1007/s00330-008-1289-y. Epub 2009 Feb 4.

PMID:
19190917
13.

Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging.

Liu FY, Yen TC, Chen MY, Lai CH, Chang TC, Chou HH, Hong JH, Chen YR, Ng KK.

Cancer. 2009 Dec 1;115(23):5470-80. doi: 10.1002/cncr.24599.

14.

Clinical use of combined positron emission tomography and computed tomography in thymoma recurrence.

El-Bawab HY, Abouzied MM, Rafay MA, Hajjar WM, Saleh WM, Alkattan KM.

Interact Cardiovasc Thorac Surg. 2010 Oct;11(4):395-9. doi: 10.1510/icvts.2010.236273. Epub 2010 Jul 16.

PMID:
20639307
15.

Comparison of ¹³¹I whole-body imaging, ¹³¹I SPECT/CT, and ¹⁸F-FDG PET/CT in the detection of metastatic thyroid cancer.

Oh JR, Byun BH, Hong SP, Chong A, Kim J, Yoo SW, Kang SR, Kim DY, Song HC, Bom HS, Min JJ.

Eur J Nucl Med Mol Imaging. 2011 Aug;38(8):1459-68. doi: 10.1007/s00259-011-1809-x. Epub 2011 Apr 20.

PMID:
21505897
16.

[Combined functional and morphological imaging of sarcomas: significance for diagnostics and therapy monitoring].

Schramm N, Schlemmer M, Rist C, Issels R, Reiser MF, Berger F.

Radiologe. 2010 Apr;50(4):339-48. doi: 10.1007/s00117-009-1973-1. German.

PMID:
20221579
17.

18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.

Walter F, Federman N, Apichairuk W, Nelson S, Phelps ME, Allen-Auerbach M, Walter MA, Czernin J.

Pediatr Hematol Oncol. 2011 Oct;28(7):579-87. doi: 10.3109/08880018.2011.602180.

PMID:
21936620
18.

Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings.

Chung HH, Kang WJ, Kim JW, Park NH, Song YS, Chung JK, Kang SB, Lee HP.

Eur J Nucl Med Mol Imaging. 2007 Apr;34(4):480-6. Epub 2006 Nov 7.

PMID:
17089122
19.

"One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?

Heusner T, Gölitz P, Hamami M, Eberhardt W, Esser S, Forsting M, Bockisch A, Antoch G.

Eur J Radiol. 2011 Jun;78(3):430-5. doi: 10.1016/j.ejrad.2009.10.031. Epub 2009 Nov 27.

PMID:
19945240
20.

Supplemental Content

Support Center